Upcoming webinar


Join a practical clinical webinar focused on the role of immunotherapy in endometrial cancer, including its use in the adjuvant setting, combination strategies in the recurrent setting, and key considerations for management in routine clinical practice.
This session will be led by Dr. Stéphanie Lheureux, MD, PhD, Site Lead in Gynecology at the Princess Margaret Cancer Centre, and is designed to support clinicians in integrating recent evidence and emerging therapeutic approaches in gynecologic oncology.
Learning Objectives
At the end of this session, participants will be able to:
-
Discuss the evolving role of immunotherapy in the adjuvant treatment of endometrial cancer, including data from major clinical trials and patient selection criteria.
-
Examine and compare different immunotherapy-based combinations for the management of recurrent or metastatic endometrial cancer, highlighting efficacy, safety profiles, and guideline recommendations.
-
Describe practical aspects of implementing immunotherapy in endometrial cancer care, including patient monitoring strategies as well as the identification, prevention, and management of immune-related adverse events.

Stéphanie Lheureux,
Site Manager in Gynecology
Princess Margaret Cancer Center
Conflict of interest
Dr. Stéphanie Lheureux is an Associate Professor in the Faculty of Medicine at the University of Toronto. She is a Medical Oncologist and Clinician Investigator, and serves as Site Lead of Gynecologic Oncology and Co-Director of the High Definition Therapeutics Program at the Princess Margaret Cancer Centre. She holds the Westaway Chair in Ovarian Cancer Research. Her clinical and academic interests focus on gynecologic cancers and early drug development, with a strong emphasis on translational research. Her work has been recognized with two ASCO Merit Awards, the 2019 Career Development Award from the American Society of Clinical Oncology, and the 2021 Young Investigator Award from the University of Toronto Division of Medical Oncology. Internationally, Dr. Lheureux is Co-Chair of the Translational Research Committee and Director representing the Princess Margaret Consortium at the Gynecologic Cancer InterGroup (GCIG). She also co-leads the ETCTN Disease Focus Women’s Cancers Webinar. Dr. Lheureux is a principal investigator or co–principal investigator on multiple clinical trials and large-scale peer-reviewed funding initiatives supported by the Canadian Cancer Society Research Institute, Conquer Cancer Foundation/American Society of Clinical Oncology, Ontario Institute for Cancer Research, Ovarian Cancer Canada, and the Terry Fox.


Join a practical, clinically focused webinar dedicated to optimizing care for patients with platinum-resistant recurrent ovarian cancer, a setting characterized by rapidly evolving definitions, therapeutic options, and clinical evidence.
This session will be led by Robert Coleman and is designed to equip clinicians with the tools to interpret and apply emerging evidence, integrate current regulatory decisions, and strategically position novel and investigational therapies in everyday practice.
Learning Objectives
At the end of this session, participants will be able to:
-
Define and apply the current taxonomy for platinum-resistant recurrent ovarian cancer and explain how the timing of resistance affects eligibility, endpoints, and interpretation of clinical trial data.
-
Translate recent FDA decisions and label updates into practical, multidisciplinary care pathways by selecting appropriate candidates, identifying required testing and biomarkers, and implementing safe administration and toxicity-mitigation practices (e.g., ADC-specific and immune-related adverse events), including drug–drug interaction considerations.
-
Critically appraise the contemporary investigational landscape (e.g., ADCs, immune combinations, DDR and kinase inhibitors) to propose evidence-based sequencing strategies and strategic considerations for patient care.

Robert L. Coleman, MD, FACOG, FACS
Chief Medical Officer
Vaniam Group
Conflict of interest coming soon
Dr. Coleman completed his Obstetrics & Gynecology residency at Northwestern University Medical Center in Chicago, Illinois, and completed his fellowship at The University of Texas MD Anderson Cancer Center in 1993. From 1993-1996, he served as Assistant Professor at Creighton University followed by service as Vice-Chairman, Department of Obstetrics and Gynecology at the University of Texas, Southwestern Medical Center. Dr. Coleman joined as Faculty at MD Anderson Cancer center in 2004 and served as Professor and Executive Director for Cancer Network Research, holding the Ann Rife Cox Chair in Gynecology. In March 2020, he joined US Oncology Research (USOR) as Chief Scientific Officer and served briefly as Chief Medical Officer for Sarah Cannon Research Institute (SCRI). He practices at Texas Oncology, US Oncology Network and currently serves as Chief Medical officer for Vaniam Group. He also serves as Vice President, GOG Foundation and is Special Advisor to the President for GOG Partners. Dr. Coleman has authored or coauthored over 800 scientific publications, including over 470 peer-reviewed articles, along with numerous book chapters, monographs, invited articles, and textbooks. He was the 2019 APGO-CREOG awardee for Excellence in Teaching. He served as President of SGO (2015-2016) and President of IGCS (2020-2022). He was recently inducted into MJH Life Sciences™ 2020 class of “Giants in Cancer Care®.”

Scientific Committee
Past Webinars
Join us for a practical, case-based webinar led by experts Dr. Maxime Rioux and Dr. Maxime Chénard-Poirier, designed to strengthen your knowledge and clinical skills in applying the RECIST criteria (Response Evaluation Criteria in Solid Tumors). This session addresses a significant practice gap in the consistent use of RECIST and aims to support better decision-making in oncology.
Learning objectives
By the end of this presentation, participants will be able to:
-
Familiarize yourself with the RECIST criteria.
-
Describe several examples of RECIST application in routine clinical practice.
This activity is an accredited group learning activity (Section 1) as defined by the Maintenance of Certification (MOC) Program of the Royal College of Physicians and Surgeons of Canada, as well as a recognized professional development activity (Category A) as defined by the Collège des médecins du Québec. This activity has been approved by the Continuing Professional Development (CPD) Directorate of the Fédération des médecins spécialistes du Québec.
You may claim a maximum of 1.5 hours under Section 1 / recognized professional development activity (Category A). Participants should claim only the number of hours that corresponds to the duration of their participation.

Maxime Rioux
Radiologist
CHU de Québec
Conflict of interest
Dr. Maxime Rioux is a diagnostic radiologist in the Department of Medicine at Université Laval, with specialized expertise in abdominal and pelvic imaging. He plays a key role in multidisciplinary oncology care by providing precise interpretation of imaging studies to support informed clinical decision-making.
Maxime Chénard-Poirier, MD, FRCPC
Medical Oncologist and Hematologist
CHU de Québec - Université Laval
Conflict of interest
Dr. Maxime Chénard-Poirier is a Clinical Professor in the Department of Medicine at the Faculty of Medicine, Université Laval, and an Associate Researcher in the Oncology Axis at the Hôtel-Dieu de Québec (HEJ) research centre

Scientific Committee
This content was developed by the RGOQ with an unrestricted grant from the following sponsor: Merck Canada. The sponsor had no role in the development of the content, the selection of topics, or the choice of speakers. The views expressed in this presentation are solely those of the authors/speakers: Dr. Maxime Rioux and Dr. Maxime Chénard-Poirier.
Discover practical tips and cutting-edge information with Dr. Vincent Castonguay (Université Laval), as we explore how combining first-line chemotherapy and immunotherapy can transform outcomes for patients with recurrent or advanced endometrial cancer.
Learning objectives
By the end of this presentation, participants will be able to:
-
Evaluate the role of first-line chemotherapy combined with immunotherapy in the management of recurrent or advanced endometrial cancer, integrating current evidence and clinical trial results to guide therapeutic decisions.
-
Analyze the mechanisms of action and synergistic effects of immunotherapy when combined with chemotherapy, with a focus on their application in gynecologic oncology.
-
Apply updated protocols and guidelines for the treatment of recurrent or advanced endometrial cancer in clinical practice, taking into account patient-specific factors and multidisciplinary collaboration with pathologists and oncologists.
-
Discuss innovative approaches in gynecologic oncology, including the integration of molecular pathology and immunotherapy, to improve diagnostic and therapeutic strategies through interdisciplinary collaboration.
-
Identify potential challenges and adverse effects associated with combined chemotherapy and immunotherapy regimens, developing strategies to minimize risks and optimize outcomes for patients.
This activity is an accredited group learning activity (Section 1) as defined by the Maintenance of Certification (MOC) Program of the Royal College of Physicians and Surgeons of Canada, as well as a recognized professional development activity (Category A) as defined by the Collège des médecins du Québec. This activity has been approved by the Continuing Professional Development (CPD) Directorate of the Fédération des médecins spécialistes du Québec.
You may claim a maximum of 1.5 hours under Section 1 / recognized professional development activity (Category A). Participants should claim only the number of hours that corresponds to the duration of their participation.

Vincent Castonguay
Hematologist-oncologist
CHU-de-Québec
Conflict of interest
Vincent Castonguay has been a hematologist-oncologist at the CHU de Québec since 2012. He completed his residency in hematology and oncology at Université Laval, followed by a fellowship at the Princess Margaret Hospital in Toronto specializing in gynecologic malignancies and phase I clinical trials. His main clinical and research interests are in uro-oncology and gynecologic oncology. He served as Director of the Medical Oncology Program at Université Laval from 2014 to 2023 and is currently Co-Chief of the Hematology-Oncology Department at the CHU de Québec.
This content was developed by the RGOQ with an unrestricted grant from the following sponsor: Merck Canada. The sponsor had no role in the development of the content, the selection of topics, or the choice of speaker. The views expressed in this presentation are solely those of the author/speaker: Dr. Vincent Castonguay.
Scientific Committee
Webinar resource
This webinar resource provides a concise overview of ovarian cancer, highlighting key facts on risk factors, symptoms, diagnosis, and treatment approaches. It also explains the concept of platinum sensitivity versus resistance to guide therapeutic decisions. Designed to support clinical discussions and continuing education, this resource offers clear, evidence-based insights.


.png)
.png)
.png)











.png)
.png)
